Ehab Bakbak

St. Michael's Hospital Of Unity Health Toronto
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.

Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.

Journal: European heart journal

Published: July 06, 2025

GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes.

GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes.

Journal: American journal of physiology. Heart and circulatory physiology

Published: June 14, 2024

GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage.

GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage.

Journal: American journal of physiology. Heart and circulatory physiology

Published: March 01, 2024

Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.

Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.

Journal: Med (New York, N.Y.)

Published: January 17, 2024

Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling.

Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling.

Journal: American journal of physiology. Heart and circulatory physiology

Published: September 29, 2023

Vascular regenerative cells in cardiometabolic disease.

Vascular regenerative cells in cardiometabolic disease.

Journal: Current opinion in cardiology

Published: September 05, 2023

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial.

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial.

Journal: BMC cardiovascular disorders

Published: May 03, 2023

Vascular Regenerative Cell Deficiencies in South Asian Adults.

Vascular Regenerative Cell Deficiencies in South Asian Adults.

Journal: Journal of the American College of Cardiology

Published: February 27, 2023

Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.

Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.

Journal: Circulation

Published: November 06, 2022

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease.

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease.

Journal: Med (New York, N.Y.)

Published: October 27, 2022

Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity.

Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity.

Journal: Cardiovascular research

Published: July 12, 2022

Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?

Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?

Journal: Reviews in endocrine & metabolic disorders

Published: June 23, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026